Treatment of refractory chronic lymphocytic leukemia with prednimustine: A phase II study using strict response criteria

David R Gandara, Christopher B. George, Curt A. Ries, Maria M. Koretz, Jerry P. Lewis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Twenty-one patients with refractory chronic lymphocytic leukemia (CLL) were entered into this Northern California Oncology Group (NCOG) study of prednimustine, an ester of chlorambucil and prednisolone. All patients had active disease and were refractory to standard alkylating agent chemotherapy. Treatment consisted of prednimustine 100 mg/m2/day orally for 3 consecutive days every 2 weeks. By strict response criteria used in this study there was one complete remission (CR), no partial remissions (PR), and three cases of clinical improvement (CI) in 18 evaluable patients, for a total response rate of 22%. The median duration of response is 20+ months, with two patients continuing to respond. Toxicity of this intermittent prednimustine regimen consisted primarily of mild to moderate thrombocytopenia and neutropenia. No episodes of treatment-associated infection or hemorrhage occurred, and nonhematologic toxicity was minor. Using strict response criteria, this study fails to confirm previous reports of high response rates for prednimustine in patients with CLL refractory to standard therapy. The significance of the response category of clinical improvement in CLL is demonstrated by the substantial improvement in objective parameters and the long duration of response. This study also emphasizes the need for standardization of response criteria for this disease.

Original languageEnglish (US)
Pages (from-to)165-168
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume19
Issue number2
DOIs
StatePublished - Apr 1987

Fingerprint

Prednimustine
B-Cell Chronic Lymphocytic Leukemia
Refractory materials
Toxicity
Chlorambucil
Oncology
Chemotherapy
Alkylating Agents
Therapeutics
Prednisolone
Standardization
Esters
Neutropenia
Thrombocytopenia
Hemorrhage
Drug Therapy
Infection

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Treatment of refractory chronic lymphocytic leukemia with prednimustine : A phase II study using strict response criteria. / Gandara, David R; George, Christopher B.; Ries, Curt A.; Koretz, Maria M.; Lewis, Jerry P.

In: Cancer Chemotherapy and Pharmacology, Vol. 19, No. 2, 04.1987, p. 165-168.

Research output: Contribution to journalArticle

Gandara, David R ; George, Christopher B. ; Ries, Curt A. ; Koretz, Maria M. ; Lewis, Jerry P. / Treatment of refractory chronic lymphocytic leukemia with prednimustine : A phase II study using strict response criteria. In: Cancer Chemotherapy and Pharmacology. 1987 ; Vol. 19, No. 2. pp. 165-168.
@article{cb5286a9d0c64052b444f90b5c84f430,
title = "Treatment of refractory chronic lymphocytic leukemia with prednimustine: A phase II study using strict response criteria",
abstract = "Twenty-one patients with refractory chronic lymphocytic leukemia (CLL) were entered into this Northern California Oncology Group (NCOG) study of prednimustine, an ester of chlorambucil and prednisolone. All patients had active disease and were refractory to standard alkylating agent chemotherapy. Treatment consisted of prednimustine 100 mg/m2/day orally for 3 consecutive days every 2 weeks. By strict response criteria used in this study there was one complete remission (CR), no partial remissions (PR), and three cases of clinical improvement (CI) in 18 evaluable patients, for a total response rate of 22{\%}. The median duration of response is 20+ months, with two patients continuing to respond. Toxicity of this intermittent prednimustine regimen consisted primarily of mild to moderate thrombocytopenia and neutropenia. No episodes of treatment-associated infection or hemorrhage occurred, and nonhematologic toxicity was minor. Using strict response criteria, this study fails to confirm previous reports of high response rates for prednimustine in patients with CLL refractory to standard therapy. The significance of the response category of clinical improvement in CLL is demonstrated by the substantial improvement in objective parameters and the long duration of response. This study also emphasizes the need for standardization of response criteria for this disease.",
author = "Gandara, {David R} and George, {Christopher B.} and Ries, {Curt A.} and Koretz, {Maria M.} and Lewis, {Jerry P.}",
year = "1987",
month = "4",
doi = "10.1007/BF00254572",
language = "English (US)",
volume = "19",
pages = "165--168",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Treatment of refractory chronic lymphocytic leukemia with prednimustine

T2 - A phase II study using strict response criteria

AU - Gandara, David R

AU - George, Christopher B.

AU - Ries, Curt A.

AU - Koretz, Maria M.

AU - Lewis, Jerry P.

PY - 1987/4

Y1 - 1987/4

N2 - Twenty-one patients with refractory chronic lymphocytic leukemia (CLL) were entered into this Northern California Oncology Group (NCOG) study of prednimustine, an ester of chlorambucil and prednisolone. All patients had active disease and were refractory to standard alkylating agent chemotherapy. Treatment consisted of prednimustine 100 mg/m2/day orally for 3 consecutive days every 2 weeks. By strict response criteria used in this study there was one complete remission (CR), no partial remissions (PR), and three cases of clinical improvement (CI) in 18 evaluable patients, for a total response rate of 22%. The median duration of response is 20+ months, with two patients continuing to respond. Toxicity of this intermittent prednimustine regimen consisted primarily of mild to moderate thrombocytopenia and neutropenia. No episodes of treatment-associated infection or hemorrhage occurred, and nonhematologic toxicity was minor. Using strict response criteria, this study fails to confirm previous reports of high response rates for prednimustine in patients with CLL refractory to standard therapy. The significance of the response category of clinical improvement in CLL is demonstrated by the substantial improvement in objective parameters and the long duration of response. This study also emphasizes the need for standardization of response criteria for this disease.

AB - Twenty-one patients with refractory chronic lymphocytic leukemia (CLL) were entered into this Northern California Oncology Group (NCOG) study of prednimustine, an ester of chlorambucil and prednisolone. All patients had active disease and were refractory to standard alkylating agent chemotherapy. Treatment consisted of prednimustine 100 mg/m2/day orally for 3 consecutive days every 2 weeks. By strict response criteria used in this study there was one complete remission (CR), no partial remissions (PR), and three cases of clinical improvement (CI) in 18 evaluable patients, for a total response rate of 22%. The median duration of response is 20+ months, with two patients continuing to respond. Toxicity of this intermittent prednimustine regimen consisted primarily of mild to moderate thrombocytopenia and neutropenia. No episodes of treatment-associated infection or hemorrhage occurred, and nonhematologic toxicity was minor. Using strict response criteria, this study fails to confirm previous reports of high response rates for prednimustine in patients with CLL refractory to standard therapy. The significance of the response category of clinical improvement in CLL is demonstrated by the substantial improvement in objective parameters and the long duration of response. This study also emphasizes the need for standardization of response criteria for this disease.

UR - http://www.scopus.com/inward/record.url?scp=0023248270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023248270&partnerID=8YFLogxK

U2 - 10.1007/BF00254572

DO - 10.1007/BF00254572

M3 - Article

C2 - 3568275

AN - SCOPUS:0023248270

VL - 19

SP - 165

EP - 168

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -